A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety

Journal of Clinical Psychiatry

Volumn 58, Issue 3, 1997, Pages 112-118

  Ravindran, Arun V ^a,c   Judge, Rajinder ^b   Hunter, Brian N ^b   Bray, Julia ^b   Morton, Niklas H ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; NEFAZODONE; PAROXETINE; PLACEBO; TEMAZEPAM; VENLAFAXINE;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEXUAL DYSFUNCTION; XEROSTOMIA;

EID: 0030942809     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n0305     Document Type: Article

References (32)

1. Wittchen H-U, Essau CA. Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? J Clin Psychiatry 1993;54(1, suppl):9-15
2. Tennant C, Hurry J, Bebbington P. The short-term outcome of neurotic disorders in the community, demographic and clinical predictors of remission. Aust N Z J Psychiatry 1981;15:111-116
3. Hamilton M. Distinguishing between anxiety and depressive disorders. In: Last CA, Hersen M. eds. Handbook of Anxiety Disorders. New York, NY: Pergamon Press; 1988:143-155
4. Barlow DH, DiNardo PA, Vermilyea BB, et al. Comorbidity and depression among the anxiety disorders: issues in diagnosis and classification. J Nerv Ment Dis 1986;174:63-72
5. Clayton PJ. The comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry 1990:51(11, suppl):35-39
6. Murphy JM, Olivier DC, Sobol AM, et al. Diagnosis and outcome: depression and anxiety in a general population. Psychol Med 1986;16:117-126
7. Ormel J, Oldehinkel T, Brilman E, et al. Outcome of depression and anxiety in primary care: a three-wave 31/2-year study of psychopathology and disability. Arch Gen Psychiatry 1993;50:759-766
8. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychiatry 1991;148:1512-1517
9. Fawcett J. Suicide risk factors in depressive disorders and in panic disorder. J Clin Psychiatry 1992;53(3, suppl):9-13
10. Eison MS. Serotonin: a common neurobiologic substrate in anxiety and depression. J Clin Psychopharmacol 1990;10:26S-30S
11. Feighner JP, Boyer WF, Meredith CH, et al. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989;4:239-244
12. Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 1991;159:394-398
13. Huitieldt B, Montgomery SA. Comparison between zimelidme and amitriptyline of efficacy and adverse symptoms: a combined analysis of four British clinical trials in depression. Acta Psychiatr Scand 1983;68(308, suppl):55-69
14. Wakelin JS. The role of serotonin in depression and suicide: do serotonin reuptake inhibitors provide a key? Adv Biol Psychiatry 1988;17:70-83
15. Hutchinson DR, Tong S, Moon CAL. et al. A double-blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients. Br J Clin Res 1991;2:43-57
16. Claghorn JL, Kiev A, Rickels K, et al. Paroxetine versus placebo: a double-blind comparison in depressed patients. J Clin Psychiatry 1992;53: 434-438
17. Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry 1992;53(2, suppl):52-56
18. Dunbar GC, Fuell DL. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 1992;6 (4, suppl):81-90
19. Stott PC, Aitken CA. A double-blind comparison of paroxetine and amitriptyline in community patients with depression and associated anxiety. In: New Research Program and Abstracts of the 146th Annual Meeting of the American Physicians Association; May 26,1993; San Francisco, Calif. Abstract NR460:175-176
20. Montgomery SA, Asberg M. A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
21. Snaith RP, Baugh SJ, Clayden AD, et al. The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 1982;141:518-523
22. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
23. Ancil RJ, Poyser J, Davey A, et al. Management of mixed affective symptoms in primary care: a critical experiment. Acta Psychiatr Scand 1984;70:463-469
24. Swinson RP. The acute treatment of anxiety and depression. Psychiatr J Univ Ottawa 1989;14:375-380
25. Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 1990;81:185-189
26. Rickels K, Schweizer E. The treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychiatry 1993;54(I suppl.) 20-23
27. Cookson J. Side effects of antidepressants. Br J Psychiatry 1993;163(20, suppl):20-24
28. Link C, Dunbar GC. An overview of studies comparing the efficacy, safety and tolerability of paroxetine and clomipramine. Nord J Psychiatry 1992;27(suppl):17-22
29. Feighner JP, Pambakian R, Fowler RC, et al. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989;25:219-221
30. Schweizer E, Feighner J, Mandos LA, et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-108
31. Montgomery SA. The advantages of paroxetine in different subgroups of depression. In: Montgomery SA, ed. Selective Serotonin Reuptake Inhibitors in Psychiatric Practice. Oxford, England: Rapid Communications; 1992:91-100
32. Judd FK, Burrows GD. Anxiety disorders and their relationship to depression. In: Paykel FS, ed. Handbook of Affective Disorders. New York, NY: Guilford Press; 1992:77-87